Updated Trial and Real-World Data Show Benefit of Ide-Cel for Multiple Myeloma
Abdullah M. Khan, MBBS, discusses the recent updates to data on the use of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Ide-Cel Shows Benefit for Multiple Myeloma After 2 to 4 Lines of Therapy
Abdullah M. Khan, MBBS, discusses the pivotal phase 3 KarMMa-3 trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
CAR T-Cell Therapy Significantly Impacts R/R Multiple Myeloma
During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the benefits of using CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.